Protein molecular models enable predictive identification
of aqueous-exposed sequences as potentially suitable epitopes
for synthetic antibody development programs
BioInformatics
Larial provides upstream and downstream bioinformatics support for
various client projects. Depending on the exact sequence of events
called for in a particular scientific algorithm it may be necessary to
obtain structural information on a particular protein target prior to
undertaking experimental work. Genetic information may be all that is
available prior to initiation of a projected designed to deduce a
particular protein's function or structure. Psi blasting and subsequent
homology modelling of aligned sequences is often the only possible route
towards assembling a putative protein structure that can be tested
experimentally. Similarly, hydropathy analysis of membrane protein
sequences provides some limited predictive knowledge of possible
topologies for ion channels, transporters, receptors etc. Such
information can be helpful in strategizing experimental programs focused
on construction of synthetic peptide immunogens or site-directed
mutagenesis studies that are designed to assess the functional roles of
different membrane protein domains. Predictions of protein
conformational states or the interaction of specific domains within or
between homologous/heterologous subunits is another valuable asset that
helps support experimental design and testing.
It may also be necessary to deploy bioinformatics tools in order to fit
experimental datasets into revised predictions of protein structure.
This is often the case when entries are already available within the
structural database but experimental data suggests alternative protein
conformations may be possible. For example it is often necessary to
remodel protein structures once mutational changes have occurred or
chimeric proteins have been assembled. This so called "downstream"
bioinformatics support often provides private sector clients with
additional IP to strengthen patent claims and academic clients with more
compelling evidence to support early stage discoveries and scientific
publications.